Prostate Health Market Report 2026

The prostate health market size has grown strongly in recent years. It will grow from $37.23 billion in 2025 to $40.69 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing aging male population, rising incidence of benign prostate conditions, wider access to urology services, availability of pharmacological prostate treatments, improved health awareness among men.

The prostate health market size is expected to see strong growth in the next few years. It will grow to $57.39 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to growing adoption of personalized prostate care plans, rising use of digital health platforms, expansion of preventive healthcare programs, increasing demand for minimally invasive therapies, greater emphasis on long-term prostate wellness. Major trends in the forecast period include increasing focus on preventive prostate healthcare, rising adoption of non-invasive treatment options, growing demand for lifestyle and nutritional interventions, expansion of digital health monitoring solutions, enhanced emphasis on early screening and awareness.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate health market in the coming years. Prostate cancer develops when cells in the prostate gland multiply uncontrollably, most commonly presenting as adenocarcinomas, which represent the most frequent form of the disease in men. The rising incidence of prostate cancer is largely attributed to an expanding aging population, greater adoption of screening practices, and lifestyle factors such as obesity and physical inactivity. Prostate health plays a critical role in the prevention, early diagnosis, and effective management of prostate cancer. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit organization, approximately 288,300 new cases of prostate cancer were projected to be diagnosed in the United States in 2023, with an estimated 34,700 deaths attributed to the disease. Therefore, the growing prevalence of prostate cancer is fueling the expansion of the prostate health market.

Major companies operating in the prostate health market are emphasizing technological innovations, including AI-powered risk assessment tools, to strengthen their competitive position. AI-based risk assessment leverages artificial intelligence algorithms to analyze clinical and biological data, predict potential risks, and support more informed clinical decision-making. For instance, in September 2024, Nanostics Inc., a Canada-based clinical-stage biotechnology company, in collaboration with Protean BioDiagnostics, a US-based biotechnology firm, launched CDX Prostate, a diagnostic tool designed for men at risk of aggressive prostate cancer. This solution integrates biological markers, clinical data, and AI-driven learning models to generate a risk score for aggressive prostate cancer. CDX Prostate uses advanced machine learning algorithms to evaluate multiple biological and clinical parameters, offering a more accurate assessment of aggressive prostate cancer risk compared to conventional approaches. The test supports healthcare providers and patients in determining whether to proceed with a biopsy following elevated prostate-specific antigen levels or abnormal digital rectal examination results.

In June 2024, Lantheus Holdings Inc., a US-based radiopharmaceutical-focused company, acquired global rights to Life Molecular Imaging’s RM2 for an undisclosed amount. This acquisition was intended to strengthen Lantheus’ position in prostate cancer treatment and broaden its oncology pipeline to include breast and other cancers through access to a novel radiotheranostic pair targeting the gastrin-releasing peptide receptor, including 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. Life Molecular Imaging is a Germany-based radiopharmaceutical company specializing in the development and commercialization of innovative radiopharmaceuticals that support the early detection and diagnosis of chronic and life-threatening diseases.

Major companies operating in the prostate health market are Pfizer Inc, Johnson And Johnson, Bayer AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc, Genentech Inc, Teleflex Inc, Elekta AB, Myriad Genetics Inc, Freenome, Theragenics Corporation, Roivant Sciences, Artera Inc, Veru Inc, HistoSonics Inc, Immunic Inc, Ezra, Francis Medical, Lucida Medical, Serimmune Inc, Alessa Therapeutics.

North America was the largest region in the prostate health market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the prostate health market by increasing costs of imported pharmaceuticals, medical devices, diagnostic tools, and wellness supplements used in prostate disease management. Healthcare systems in North America and Europe are most impacted due to reliance on imported therapies and devices, while Asia-Pacific faces pricing pressure on nutraceutical and treatment product supply chains. These tariffs contribute to higher treatment costs and reduced affordability for patients. However, they are also encouraging local manufacturing of prostate health products, regional formulation of therapies, and expanded domestic healthcare supply capabilities.

The prostate health market research report is one of a series of new reports that provides prostate health market statistics, including prostate health industry global market size, regional shares, competitors with a prostate health market share, detailed prostate health market segments, market trends and opportunities, and any further data you may need to thrive in the prostate health industry. This prostate health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate health refers to the overall condition and normal functioning of the prostate gland, a small organ in men responsible for producing seminal fluid. Preserving prostate health is important for urinary and reproductive functions and for preventing conditions such as prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Prostate health is influenced by factors including age, genetic background, diet, lifestyle habits, and routine medical checkups.

The primary disease indications related to prostate health include prostate cancer, benign prostatic hyperplasia, and prostatitis. Prostate cancer is a type of cancer that originates in the prostate gland and is characterized by uncontrolled growth of prostate cells, which can lead to tumor development and potential spread to other parts of the body. Available treatment options include hormonal therapy, chemotherapy, surgical procedures, and others, with products distributed through channels such as e-commerce platforms, pharmacies, and other outlets.

The prostate health market includes revenues earned by entities providing services such as diagnostic screening, medical consultations, prostate cancer treatments, minimally invasive procedures for benign prostatic hyperplasia (BPH), telemedicine consultations, and wellness programs focused on prostate health. Only goods and services traded between entities or sold to end consumers are included. The prostate health market consists of sales of pharmaceuticals, medical devices, dietary supplements, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.